On October 5, 2022 Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, reported they will present preclinical data on lead program IMT-009, a fully human monoclonal antibody against a novel immuno-oncology target CD161, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting, held both virtually and in Boston from November 8-12, 2022 (Press release, Immunitas Therapeutics, OCT 5, 2022, View Source [SID1234621751]). The company also announced the addition of Juliana Idoyaga, Ph.D., to its Scientific Advisory Board.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The SITC (Free SITC Whitepaper) presentation will demonstrate the potential of IMT-009 as a novel cancer immunotherapy to treat solid tumors and hematological malignancies.

Poster Presentation Details for IMT-009:
Title: Anti-CD161 antibody IMT-009 is a novel immunotherapeutic agent that reinvigorates T and NK cell function and anti-tumor efficacy through blocking interaction of CD161 with its ligand CLEC2D
Abstract Number: 235020
Date/Time: All poster presentations are made available by the conference on November 10, 2022.

"We are excited to present the preclinical data which supported the IND filing of IMT-009 at SITC (Free SITC Whitepaper) 2022 and are delighted to welcome Juliana to our Scientific Advisory Board at this pivotal time in Immunitas’ journey," said Seng-Lai "Thomas" Tan, Ph.D., Chief Scientific Officer of Immunitas Therapeutics. "As we progress IMT-009 into the clinic based on the data showing a potential for efficacy in various types of tumors, we will also continue advancing our pipeline of next generation differentiated immunotherapies. Juliana’s vast expertise in the basic biology of dendritic cells and their applications towards therapeutics and shared passion for discovering possible applications of novel immuno-oncology therapeutics is a great addition as we expand our pipeline."

Dr. Idoyaga is currently an Assistant Professor in the Department of Microbiology and Immunology at Stanford University School of Medicine, where she is leading research on dendritic cell subset tissue localization, function and the potential applications of dendritic cell-targeted vaccines and therapies.

Dr. Idoyaga received her B.S. in Biology and Immunology from the Buenos Aires University in Argentina. She then completed her Ph.D. in Immunology and Biomedical Sciences with honors at the National Autonomous University of Mexico. She performed her postdoctoral training in the laboratory of Cellular Physiology and Immunology at The Rockefeller University before joining Stanford University’s faculty and serving as the chair of the CDIII (Community, Diversity and Inclusion in Immunology) Committee. During her career, Dr. Idoyaga has earned many awards including NIH Pathway to Independence Award, the NIH Director’s New Innovator Award, Baxter Foundation Faculty Scholar Award, and the Gabilan Faculty Fellow Award.

The SITC (Free SITC Whitepaper) poster presentation will be available on the Immunitas Therapeutics website on November 10, 2022.

About IMT-009

IMT-009 is an Fc-attenuated monoclonal antibody that binds with high affinity and selectivity to CD161, a receptor that is broadly expressed on NK and a subset of memory T cells, blocking interactions between the receptor and its cognate ligand, CLEC2D, which is expressed on the surface of both cancer cells and immune cells. Preclinical data confirm that CD161 blockade with IMT-009 results in enhanced anti-tumor activity. IMT-009 is anticipated to begin enrollment for a Phase 1/2a clinical trial in Q4 2022 for use as a monotherapy and combination treatment for solid tumor and hematological malignancies. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacodynamic biomarkers, and preliminary efficacy of IMT-009 as well as identify the Recommended Phase 2 Dose (RP2D). The trial will then transition into Phase 2 with multiple expansion cohorts to assess the safety and efficacy of IMT-009 alone or in combination with another antineoplastic agent.

On October 5, 2022 AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") reported an update on the Company’s share repurchase program (the "Share Repurchase Program") authorized by the Company’s Board of Directors on January 21, 2022 (Press release, AIkido Pharma, OCT 5, 2022, View Source [SID1234621750]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company reported that on October 4, 2022, the Company purchased 38,035 shares of common stock at $6.99 per share. Anthony Hayes, CEO of AIkido stated, "We believe the Company stock continues to be undervalued and we are using this opportunity to enhance shareholder value by reducing the amount of stock that is outstanding."

Additional shares may be repurchased from time to time in open market transactions, or other means in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 10b -18 of the Exchange Act. The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, including blackout period restrictions.

On October 5, 2022 Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immune-oncology company, reported that an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2022 (Press release, Lytix Biopharma, OCT 5, 2022, View Source [SID1234621749]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract will be released on the SITC (Free SITC Whitepaper) website 7 November 14:00 CEST. The poster is scheduled for presentation during the SITC (Free SITC Whitepaper) meeting 8-12th November 2022.

Poster Details:

Abstract Title: Molecular mechanisms of DC activation by melanoma cells responding to LTX-315.

Presenter: Takahiro Yamazaki, Department of Radiation Oncology, Weill Cornell Medical College, New York, USA

About SITC (Free SITC Whitepaper)

The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.

As the largest conference solely focused on cancer immunotherapy, the Annual meeting provides international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.

On October 5, 2022 Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) reported that filing of a provisional patent application with the USPTO entitled "Enhancement of T Cell Homing to Tumors Through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion" with the United States Patent and Trademark Office (Press release, Regen BioPharma, OCT 5, 2022, View Source [SID1234621748]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent application discloses novel means of generating CAR-T cells which upon activation stimulate production of various T cell-specific compounds, called "chemokines" which act as molecular beacons that call in all surrounding T cells and instruct them to kill the cancer cell.

According to an industry report, "Overall, the global CAR-T cell market for all indications was worth $1.7 billion in 2021 and is forecast to reach $2.4 billion by the end of 2022. By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. This makes CAR-T cells one of the fastest growing and potentially profitable therapeutic areas in oncology[1]."

"Despite the significant market size of CAR-T cells, this approach has only shown benefit in so called "liquid tumors", which as leukemias and lymphomas. Overall, for reasons known and unknown, solid tumors such as breast, lung, colon, skin and kidney cancer have not benefited" Said David Koos, President, CEO and Chairman. "Our scientific advisors and collaborators tell us that one of the shortcomings of current treatments is that they rely exclusively on the engineered CAR-T cells, which usually are inactivated by the tumor. In the current patent filed we overcome this by using the initial CAR-T cells to stimulate a chain reaction that culminates in education of the patient’s immune response to kill the tumor."

The Company previously has obtained issued US patent #11,090,332 (which covers means of generating T cell immune responses to the solid tumor antigen survivin) as well as US Patent # 11,141,471 covering NR2F6 silenced CAR-T. By combining these technologies with the ones disclosed in the abovementioned patent application filing the Company anticipates development of novel and potentially effective CAR-T cells capable of killing solid tumors, which would significantly expand the market of this new therapy.

On October 5, 2022 LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, reported it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022 (Press release, LadRx, OCT 5, 2022, View Source [SID1234621747]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chief Executive Officer Stephen Snowdy, PhD commented, "Following up on other changes we have made this year, including the change of our name to LadRx Corporation, we are updating our ticker symbol to better reflect our Company’s focus and brand. Our new name and ticker highlight our unique product platform that has given rise to one clinical drug, Aldoxorubicin, and four pre-clinical therapeutics targeted against cancer, LADRs 7, 8, 9, and 10."

There is no action required by the Company’s current shareholders and the change in its ticker symbol will have no effect on its corporate structure or business. LadRx’s common stock will continue to be listed on the OTCQB, and the CUSIP will remain unchanged.